Novavax, Inc. (NVV1.F)

6.876 €

+0.18 (+2.66%)
Symbol NVV1.F
Price 6.876 €
Beta 1.710
Volume Avg. 0.00M
Market Cap 593.434M
Shares () -
52 Week Range 5.252-75.56
1y Target Est -
DCF Unlevered NVV1.F DCF ->
DCF Levered NVV1.F LDCF ->
ROE 169.61% Strong Buy
ROA -29.13% Sell
Operating Margin -
Debt / Equity -456.21% Strong Sell
P/E -0.55
P/B -0.87


Consensus EPS

Upgrades & Downgrades

Mr. John Charles Jacobs M.B.A.

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.